Melbourne, Australia, 30th January 2025 – A groundbreaking precision medicine system developed by Australian biotech trailblazer Diag-Nose.io is set to transform the management of chronic respiratory diseases worldwide after closing its seed round this week. Originally established at the Stanford ENT Innovation Program and now based in Melbourne, Diag-Nose.io is pioneering advancements in respiratory healthcare by focusing on the “unified airway”; the biological relationship between the lungs and nasal passages.
Traditional diagnostic methods for chronic respiratory conditions - such as asthma and chronic obstructive pulmonary disorder (COPD) - rely on outdated measurement tools and subjective assessments. These flawed processes currently result in treatment failure for more than 30% of patients, costing hundreds of millions of dollars per year.
Using artificial intelligence and protein signatures, Diag-Nose.io’s RhinoMAP removes the guesswork, enabling clinicians to match treatments to a patient’s unique biological profile, or “endotype.”
A nasal sample is collected using Diag-Nose.io’s patented nasal liquid biopsy device and analysed. The data is then uploaded into RhinoMAP, an AI-powered biomarker analytics platform to determine disease progression and therapeutic responsiveness and in the long-term differential diagnostic recommendation.
“Over a third of Australians suffer from chronic respiratory conditions, and globally, these diseases impact more than 450 million people, resulting in approximately four million deaths in 2019,” said Eldin Rostom, CEO and Co-Founder of Diag-Nose.io. “Together with the new biologics medicines, our RhinoMAP system will bring us one step closer towards the holy grail of respiratory medicine; helping patients become completely free of symptoms. This progress is only made possible thanks to the dedicated support and investment from visionary partners who share our mission.
The oversubscribed $3.15M raise was led by Breakthrough Victoria. Additional funding comes from Radar Ventures, Specialty Physician Associates, biotech executives Carl Stubbings - who will also be appointed to the Board, Stephen Ho and Richard Lipscombe alongside an international syndicate of physicians from leading hospitals including Houston Methodist and Mount Sinai.
-ENDS-
Key Facts:
- Diag-Nose.io Closes Oversubscribed $3.15M Seed Round
- Brings new hope for Aussie asthma sufferers with "AI enabled unified airway"
- Asthma deaths have returned to pre-pandemic levels.
- One third of Australian's suffer from chronic respiratory conditions, and globally, these diseases impact more than 450 million people, resulting in approximately four million deaths.
- Outdated measurement tools mean diagnosis and treatment fails in more than 30% of patients.
About us:
ABOUT DIAG-NOSE.IO
Diag-Nose.io, founded in 2020 and headquartered in Melbourne, Australia, is a biotechnology company focused on translating the complexities of the unified airway into precision diagnostic and drug discovery solutions.
Their precision medicine technology combines advanced proteomics, computational biology, and AI (machine learning) to create a scalable respiratory biology model. This innovation aims to help clinicians prescribe the right treatments faster and enable researchers to accelerate the development of new therapies.
The company’s flagship platform, RhinoMAP™, leverages proteomic data to predict respiratory disease activity, monitor therapy response and predict treatment efficacy in advance, with an initial focus on anti-Th2 biologics.
Contact details:
For any questions in relation to this release or to discuss interviews, please contact:
Nicole Papoutsis
0422 418 099
